Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported recently in AIDS-related Kaposi's sarcoma, a tumour of endothelial cell origin. The high vascularity and responsiveness to immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Deplanque, G, Madhusudan, S, Jones, P H, Wellmann, S, Christodoulos, K, Talbot, D C, Ganesan, T S, Blann, A, Harris, A L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409952/
https://www.ncbi.nlm.nih.gov/pubmed/15354209
http://dx.doi.org/10.1038/sj.bjc.6602126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409952/
https://www.ncbi.nlm.nih.gov/pubmed/15354209
http://dx.doi.org/10.1038/sj.bjc.6602126

Ejemplares similares